Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.

NCT00384423 is registered in ClinicalTrials.gov with Epix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00384423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00384423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.
Lead sponsor
Epix Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2006
Completion date
Not reported
Enrollment
80 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease